DK1689404T3 - Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer - Google Patents

Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer

Info

Publication number
DK1689404T3
DK1689404T3 DK04798717T DK04798717T DK1689404T3 DK 1689404 T3 DK1689404 T3 DK 1689404T3 DK 04798717 T DK04798717 T DK 04798717T DK 04798717 T DK04798717 T DK 04798717T DK 1689404 T3 DK1689404 T3 DK 1689404T3
Authority
DK
Denmark
Prior art keywords
combination
cancer
fluoracil
prodrugs
treatment
Prior art date
Application number
DK04798717T
Other languages
English (en)
Inventor
Mary Ellen Rybak
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Application granted granted Critical
Publication of DK1689404T3 publication Critical patent/DK1689404T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK04798717T 2003-11-13 2004-11-15 Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer DK1689404T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51969003P 2003-11-13 2003-11-13
PCT/GB2004/050026 WO2005049031A1 (en) 2003-11-13 2004-11-15 Combination

Publications (1)

Publication Number Publication Date
DK1689404T3 true DK1689404T3 (da) 2009-01-26

Family

ID=34619369

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04798717T DK1689404T3 (da) 2003-11-13 2004-11-15 Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer

Country Status (15)

Country Link
US (1) US7622458B2 (da)
EP (1) EP1689404B9 (da)
JP (1) JP2007511499A (da)
AT (1) ATE406897T1 (da)
CA (1) CA2544320A1 (da)
CY (1) CY1108629T1 (da)
DE (1) DE602004016376D1 (da)
DK (1) DK1689404T3 (da)
ES (1) ES2314470T3 (da)
HR (1) HRP20080598T3 (da)
PL (1) PL1689404T3 (da)
PT (1) PT1689404E (da)
RS (1) RS50692B (da)
SI (1) SI1689404T1 (da)
WO (1) WO2005049031A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
CN101119750B (zh) * 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
JP2009501734A (ja) * 2005-07-21 2009-01-22 ヌボ・リサーチ・インコーポレイテッド 癌の治療方法
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
ES2569180T3 (es) 2010-11-12 2016-05-09 Pharma Mar S.A. Terapia de combinación con un alcaloide antitumoral
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN111867591A (zh) * 2018-02-12 2020-10-30 Array生物制药公司 治疗胆道癌的方法和组合疗法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
HUP0104273A3 (en) * 1998-04-06 2003-12-29 Univ Illinois Semi-synthetic ecteinascidins and pharmaceutical compositions containing them
SK285069B6 (sk) 1998-05-11 2006-05-04 Pharma Mar, S. A. Zlúčeniny, ktoré sú metabolitmi ekteinascidínu 743, farmaceutické prostriedky s ich obsahom a ich použitie
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
PT1278518E (pt) * 2000-02-28 2007-01-31 Pfizer Entpr Sarl Composição sinergetica para o tratamento do cancro colorectal
CA2406080C (en) 2000-04-12 2011-11-29 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US20020137663A1 (en) * 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
IL161430A0 (en) * 2001-10-19 2004-09-27 Pharma Mar Sa Pharmaceutical compositions containing ecteinascidin 743
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
EP1691809A1 (en) 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080242670A2 (en) 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
CN101119750B (zh) 2004-10-26 2013-03-06 法马马私人股份有限公司 抗癌治疗
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid

Also Published As

Publication number Publication date
EP1689404B9 (en) 2009-04-22
HRP20080598T3 (en) 2009-01-31
DE602004016376D1 (de) 2008-10-16
EP1689404B1 (en) 2008-09-03
PL1689404T3 (pl) 2009-02-27
JP2007511499A (ja) 2007-05-10
EP1689404A1 (en) 2006-08-16
WO2005049031A1 (en) 2005-06-02
SI1689404T1 (sl) 2009-02-28
PT1689404E (pt) 2008-12-15
US20070190164A1 (en) 2007-08-16
RS50692B (sr) 2010-06-30
US7622458B2 (en) 2009-11-24
CY1108629T1 (el) 2014-04-09
CA2544320A1 (en) 2005-06-02
ATE406897T1 (de) 2008-09-15
ES2314470T3 (es) 2009-03-16

Similar Documents

Publication Publication Date Title
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
EG25822A (en) Quinolinyl-pyrrolopyrazoles
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
HK1120441A1 (en) Drugs for treatment of ovarian cancer
NO20032027D0 (no) Effektive antitumorbehandlinger
HK1071310A1 (en) Combination therapy for the treatment of cancer
DK1827500T3 (da) Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
TW200724158A (en) Combination therapy in the treatment of cancer
DK1478362T3 (da) Kombinationsbehandling til akut myokardisk infarkt
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
TW200509922A (en) Methods of therapeutic treatment using amounts of retinoid components
NO20043774L (no) The use of devazenide as analgesic agent
NO20051601L (no) Kombinasjonsterapi med gemcitabin og zd6126
RU2002109722A (ru) Способ лечения болевого синдрома у больных хроническими соматическими заболеваниями